Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-03
1999-10-05
Cooney, Jr., John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514359, 514385, 514396, 514397, A01N 4338
Patent
active
059625007
ABSTRACT:
This invention relates to a novel method of using an Angiotensin II antagonist for the improvement of insulin sensitivity alone or in conjunction with the treatment of hypertension. Angiotensin II antagonists such as the class of substituted imidazoles represented by formula I: ##STR1## and specifically by Losartan, yl)imidazole potassium salt.
REFERENCES:
patent: 5138069 (1992-08-01), Carini et al.
patent: 5264447 (1993-11-01), Ohtawa
patent: 5266583 (1993-11-01), Ohtawa
A. Moan et al.; "Agiotensin II (AII) Receptor Antagonism with Losartan Increases Insulin Sensitivity and Decreases Sympathetic Nervous System Activity in Essential Hypertension"Inter. Soc. Hypertension, (1994).
A. Moan, et al., "The Effect Of Angiotensin II Receptor Blockade On Insulin Sensitivity And Sympathetic Nervous System Activity In Primary Hypertension", Blood Pressure, vol. 3 pp. 185-188, (1994).
A. Moan,et al., "Hypertension Therapy And Risk Of Coronary Heart Disease: How Do Antihypertensivies Affect Metabolic Factors?", Cardiology, vol. 86, pp. 89-93 (1995).
A. Moan, et al., "Angiotension II (A-II) Receptor Antagonism With Losartan Increases Insulin Sensitivity And Decreases Sympathetic Nervous System (SNS) Activity In Essential Hypertension", Int'l. Soc. Of Hypertension, pp. 21-25 (1994).
O. Iimura, et al., STN International File Biosis., STN ACC. No. 94:417516 Nineth Scientific Meeting of the Am. Society Hypertension, May 11-14, (1994), Am. J. of Hypertension 7 (4 part 2), (1994).
H. Tomiyama, et al., "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment With Angiotensin Converting Enzyme Inhibitor", Hypertension, vol. 23(4), pp. 450-455, (1994).
G. Bonner, "Hemmung des Renin-Angiotensin-Systems als Antihypertensives Prinzip", Munch. Med. Wschr., vol. 136(47), pp. 727-730, (1994).
K. Shimamoto, et al., "Effects of an Angiotensin II Receptor Antagonist, TCV-116, on Insulin Sensitivity in Fructose-Fed Rats", Blood Pressure, vol. 3(5), pp. 113-116, (1994).
H. Tomiyama, et al., "Role of Kinins in Different Responses of Insulin Sensitivity by Converting Enzyme Inhibitor, Angiotensin II Antagonist and Alpha 1-Blocker", Hypertension, vol. 20(3), p. 411, (1992).
Eide Ivar K.
Kjeldsen Sverre E.
Moan Andreas
Camara Valerie J.
Cooney Jr. John M.
Daniel Mark R.
LandOfFree
Insulin sensitivity with angiotensin II receptor blocking imidaz does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin sensitivity with angiotensin II receptor blocking imidaz, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin sensitivity with angiotensin II receptor blocking imidaz will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1172016